碩世生物(688399.SH)取得醫療器械註冊證 擴充體外診斷領域佈局
格隆匯6月6日丨碩世生物(688399.SH)發佈公吿,公司近日收到國家藥品監督管理局簽發的醫療器械註冊證(體外診斷試劑)。該產品名稱為“白色念珠菌/陰道毛滴蟲抗原聯合檢測試劑盒(乳膠免疫層析法)”,預期該產品用於體外定性檢測女性陰道分泌物中的白色念珠菌和陰道毛滴蟲抗原。
公吿表示,上述《醫療器械註冊證》的取得,豐富了公司產品種類,擴充了公司在體外診斷領域的佈局,不斷滿足多元化的臨牀需求,將增強公司綜合競爭力,有利於進一步提高公司的市場拓展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.